Variation in the sequence of T cell epitopes between dengue virus (DENV) serotypes is believed to alter memory T cell responses during second heterologous infections. We identified a highly conserved, novel, HLA-B57-restricted epitope on the DENV NS1 protein. We predicted higher frequencies of B57-NS1 26-34 -specific CD8 + T cells in PBMC from individuals undergoing secondary rather than primary DENV infection. However, high tetramer-positive T cell frequencies during acute infection were seen in only 1 of 9 subjects with secondary infection. B57-NS1 26-34 -specific and other DENV epitope-specific 
INTRODUCTION
Dengue virus (DENV), a member of the flavivirus family, consists of four distinct serotypes. Many DENV infections are asymptomatic and the majority of cases present as an acute febrile illness, dengue fever (DF). A small percentage of individuals develop dengue hemorrhagic fever (DHF), which is characterized by plasma leakage and bleeding tendency coincident with resolution of fever and clearance of viremia 1, 2 . While host-dependent factors and virus-dependent factors may influence the risk of developing DHF, prospective cohort studies have identified secondary infection with a heterologous DENV serotype as the major risk factor 3 . Additionally, it has been suggested that the order of infections modulates the risk of developing DHF [4] [5] [6] .
Antibodies and T cells are proposed to contribute to the development of severe dengue disease 7 . Non-neutralizing antibodies, through antibody dependent enhancement (ADE), may enhance viral load and immune activation 3, [8] [9] [10] . Other studies have reported higher frequencies of CD8 + T cells expressing CD69, and higher levels of immune activation markers in individuals with DHF as compared to those with DF [11] [12] [13] . Several studies have reported associations between specific HLA class I alleles and disease severity; these epidemiological links provide additional support for a role of CD8 + T cells in contributing to clinical outcome [14] [15] [16] [17] .
HLA-B57 has been associated with slow progression following HIV infection, the clearance of acute HCV infection [18] [19] [20] and is strongly associated with a number of type 2 idiosyncratic adverse drug reactions 21, 22 . The relative ability of HLA-B57 to control HIV infection correlated with unique peptide-binding characteristics that affect thymic development of CD8 + T cells 23 . A larger proportion of the naïve repertoire of T cells restricted by HLA-B57 recognized HIV viral epitopes compared to other HLA alleles.
Extended human major histocompatibility complex (MHC) haplotypes containing TNF-4
and LTA-3, together with HLA-B*48, HLA-B*57, and HLA-DPB1*0501, were detected only in patients with secondary DHF 15 .
We identified a highly conserved 9aa epitope on the NS1 protein recognized by HLA-B57-restricted T cells. We hypothesized that B57-NS1 [26] [27] [28] [29] [30] [31] [32] [33] [34] -specific CD8 + T cells would be preferentially expanded during secondary infection since the epitope sequence would be identical to that seen in primary infection. Using PBMC samples from Thai children with primary or secondary DENV infection 24 , we found that frequencies of B57-NS1 [26] [27] [28] [29] [30] [31] [32] [33] [34] tetramer-positive T cells were elevated during acute infection. Only one subject with secondary infection had particularly high frequencies of B57-NS1 26-34 + T cells (~20% of CD8 + T cells). Consistent with previous studies, expression of the activation markers CD69 and CD38 was upregulated on the total CD8 + T cell population as well as on DENVspecific T cells. In contrast, the expression of the transferrin receptor CD71 was significantly upregulated on B57-NS1 26 Table 2 
RESULTS

Identification of a highly conserved HLA-B57-restricted DENV epitope
We previously identified HLA-B57-restricted CD8 + T cell lines, which recognized the DENV NS1 or NS2a protein, using convalescent PBMC from a Thai patient with DF 25 .
As shown in Figure 1A , two representative T cell lines, 3C11 and 3F2, lysed autologous BLCLs infected with a recombinant vaccinia virus expressing the DENV-2 NS1/2a proteins.
We used pools of overlapping peptides from the NS1 protein and identified a minimal 9mer epitope recognized by these T cell lines corresponding to aa 26-34 (HTWTEQYKF) (Figure 1 B, C). Restriction of this epitope by HLA-B57 was confirmed by cytotoxicity assays using partially HLA-matched B-LCLs (data not shown). We determined the degree of conservation of NS1 [26] [27] [28] [29] [30] [31] [32] [33] [34] using the FLAVIdB database (http://cvc.dfci.harvard.edu/flavi/); this epitope was >99% conserved across >2600
sequences from all four serotypes of DENV. Comparison to previously identified CD8+ DENV epitopes indicated that this was the only epitope with such a high degree of homology (Supplemental Table 1 For ex vivo analysis of epitope-specific T cells, we obtained an HLA-B5701/NS1 [26] [27] [28] [29] [30] [31] [32] [33] [34] tetramer. We confirmed the specificity of this tetramer by showing binding to the DENVspecific T cell line 3C11, but not to an HLA-B57-restricted HIV-specific T cell line. The DENV-specific T cell line did not bind a previously described HIV-B57 tetramer (TW10-Gag; TSTLQEQIGW) ( Figure 1E ).
Detection of B57-NS1 26-34 tetramer-positive T cells in PBMC collected during acute infection
We used this B57-NS1 26-34 tetramer together with activation and phenotypic markers and performed a longitudinal analysis of B57-NS1 26-34 -specific T cells in PBMC from HLA-B*57 + subjects. We tested samples obtained at multiple time points during and after acute DENV infection from eleven HLA-B*57 children, two with primary and nine with secondary DENV infection ( Table 1 ). Figure 2D ). Only subject KPP94-037 with secondary DENV infection had high B57-NS1 26-34 -specific T cell frequencies ( Figure 2D ). Excluding this subject, frequencies of B57-NS1 26-34 + T cells were not higher in those with secondary infection compared to primary infection ( Figure 2D ).
We used tetramers for two other DENV CD8 T cell epitopes (A11-NS3 133-142 or A2-E 213-221 ) to compare the frequencies of tetramer-positive cells in subjects who were HLA-B*57 + and HLA*A11 + or HLA*A2 + ( Figure 2E ). T cell frequencies were similar for all of epitopes in PBMC from the 7 subjects tested.
Antigen-specific CD8 + T cells are highly activated during acute DENV infection
Using antibodies to CD69 and CD38, we followed CD8 + T cell activation over the course of acute dengue illness. Frequencies of CD69 + CD8 + T cells were elevated early in acute illness compared to early (1 wk after defervescence) or late (6-12 months after illness) convalescence (p<0.001), with the peak frequencies (10.7%-46.3%) occurring at or before fever day 4 ( Figure 3A We assessed CD71 expression, a marker associated with cell cycle activity 30 , on total CD8 T cells and DENV-specific T cells. Figure 4G shows representative staining of CD71 on PBMC from a subject during acute infection. CD71 expression was low on total CD8 + T cells with a mean frequency of 2.1% during acute illness (fever day -4 through fever day +3) ( Figure 4A ). In contrast, the mean frequency of B57-NS1 26 during acute illness ( Figure 4B, C) . The mean frequencies of CD71-expressing cells during acute illness were significantly higher in the CD8 + DENV-specific T cells compared to the total CD8 + population with p-values <0.0001 (Table 2 ). There were no statistically significant differences between the B57-NS1 26-34 + and the A11-NS3 133-147 /A2-E 213-221 -specific T cell populations.
Increased frequencies of CD71-expressing cells on the DENV-specific B57-NS1
The peak frequency, as determined for each donor during acute illness, of CD71 + DENV-specific CD8 T cells was also significantly higher than that of the total CD8 + T cells (p <0.005). Frequencies of CD71 + DENV-specific T cells remained higher compared to the total CD8 T cell population 1 year following infection ( Figure 4A , B, C) (p <0.0001), but were lower than the peak CD71 frequencies during acute infection in most donors. Interestingly, mean and peak frequencies of CD38 expression during acute illness were significantly higher in B57-NS1 26-34 + , but not A11-NS3 133-147 + / A2-E 213-221 + , specific T cells. CD69 expression was minimally increased only in A11-NS3 133-147 + T cells ( Figure 3 and Table 2 ). We also compared the geometric mean fluorescence intensity (gMFI) of CD71 expression between populations ( Figure 4D , E, F) and again found significant differences in the intensity of CD71 staining on the CD71 + cells during acute illness between the DENV-specific populations and total CD8 + T cells (p<0.05).
To further evaluate the expression of CD71 and its relationship to T cell activation by antigen, we stimulated a B57-NS1 26-34 -specific T cell line 3C11 with different concentrations of the NS1 26-34 peptide and measured the frequencies and intensity of CD71 expression. Figure 4H shows representative staining of CD71 expression on cell line 3C11 at 24 hours after stimulation with peptide. We detected CD71 upregulation from base line expression as early as 1 hr post stimulation with the peptide and the MFI of CD71 expression depended both on the concentration of peptide and the duration of incubation ( Figure 4I ).
CD71, CD69, CD107a and cytokine expression in epitope-specific T cell lines.
Since the NS1 [26] [27] [28] [29] [30] [31] [32] [33] [34] epitope is highly conserved with only rare variants, we next assessed CD71 expression on other DENV-specific cell lines where epitope variants are more common. We used a well characterized A11-NS3 133-147 epitope-specific cell line 10C11, which was cross reactive for the pD1 and pD3/4 variant peptides but did not recognize the pD2 variant in tetramer staining and ICS assays 31 . We stimulated 10C11
with three variant peptides for 6 hrs and evaluated the expression of CD107a, CD69, and CD71 ( Figure 5A ). We detected similar CD69 upregulation following stimulation with the pD1 and pD3/4 variant peptides. CD107a staining was more uniform following stimulation with the pD3/4 variant compared to the pD1 variant. A higher frequency of the 10C11 cell line upregulated CD71 following stimulation with the pD3/4 variant compared to the pD1 variant peptide ( Figure 5A ). We did not detect CD69, CD107a and CD71 upregulation after stimulation with the pD2 variant of the A11-NS3 133-147 epitope.
We also stimulated an A2-E 213-221 epitope-specific cell line P1A07 with four peptide variants. Cell line P1A07 had similar upregulation of CD69 following stimulation with all four peptide variants ( Figure 5B ). In contrast, there was stronger upregulation of CD71 and CD107a with the pD1 and pD2 variants compared to the pD3 and pD4 variant peptides ( Figure 5B ). We found the largest production of TNF-α and IFN-γ following stimulation with pD1 and pD2 variants and significant production following stimulation with the pD4 variant ( Figure 5C ) which matched CD71 and CD107a expression patterns. MIP-1β production was upregulated with pD4 ≈ pD1 > pD2 variant peptide stimulation. The pD3 variant peptide did not induce cytokine production ( Figure 5C ). Together, our data using cell lines suggest that CD71 expression was differentially sensitive to stimulation by homologous and heterologous variant peptides. While we may have missed the peak frequency during acute illness a second subclinical infection at the 6 month time point cannot be ruled out.
Interestingly this linear NS1 [26] [27] [28] [29] [30] [31] [32] [33] [34] epitope has been demonstrated to be an antibody epitope in mice 34 . NS1 is unique among the DENV non-structural proteins because it is secreted and expressed on cell surfaces 35 . We are unaware of other linear dengue B cell epitopes which map exactly to a CD8 T cell epitope. Since peptides presented by class I MHC come from cytosolic proteins in virally-infected cells and not from phagocytized soluble NS1, antibodies to NS1 [26] [27] [28] [29] [30] [31] [32] [33] [34] are unlikely to affect CD8 T cell responses. It is also unlikely that T cells are able to recognize this epitope on the surface or soluble NS1 since presentation of peptides on MHC molecules are critical for T cell recognition 36 .
One possible explanation for the lower-than-expected frequency of tetramerpositive cells could be differential processing and presentation of this epitope between the four serotypes. Differential processing of HIV epitopes has been shown to result in striking differences in CTL recognition 37 . We demonstrated that B57-NS1 26-34 -specific cell lines were able to lyse cells infected with any of the four DENV serotypes in vitro. Whether there is differential processing of the four serotypes for this epitope in vivo is unknown.
Alternatively, a yet unidentified factor may dampen the activation of B57-NS1 26-34 + T cells during a second infection.
Previous studies have used a number of cell surface markers to phenotype CD8 + T cells in DENV infection 12, 13, 26, 33, 38 . We included a diverse panel of surface markers including some that have not previously been studied in DENV infection, such as CD71.
The timing of expression of CD69 in this cohort was consistent with previous reports 13 and CD28 stimulation 43 , and anti-CD71 mAb abrogates CTL responses to alloantigens 44 .
Upregulation of CD71 on DENV-specific T cells may therefore indicate that these cells had a more productive activation and are more cytolytic. Our data suggest that CD71 hi expression more accurately identifies DENV-specific T cells compared to expression of CD69 and/or CD38 with significant differences in both frequency and MFI of CD71 expression between the total CD8 + T cell population and the DENV-specific populations.
Previous in vitro work showed upregulation of CD71 following αCD3 or mitogen stimulation 45, 46 . We are the first to show robust expression of CD71 on T cell lines after 
